Triple
T6005170
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Tegsedi |
E133690
|
entity |
| Predicate | belongsTo |
P35
|
FINISHED |
| Object | Ionis antisense pipeline |
E24882
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ionis antisense pipeline | Statement: [Tegsedi, belongsTo, Ionis antisense pipeline]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ionis antisense pipeline Context triple: [Tegsedi, belongsTo, Ionis antisense pipeline]
-
A.
Ionis Pharmaceuticals
chosen
Ionis Pharmaceuticals is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics using antisense technology.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
D.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
E.
Bicycle Therapeutics
Bicycle Therapeutics is a biotechnology company that develops novel therapeutics based on its proprietary bicyclic peptide (Bicycle®) platform, with a focus on targeted treatments for cancer and other serious diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f10d18081908c351170b7f58d3d |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c1088f5c84819094e4696c24c4dd79 |
completed | March 23, 2026, 9:31 a.m. |
Created at: March 22, 2026, 4:06 p.m.